Influence of 2-Methoxyestradiol and Sex on Hypoxia-Induced Pulmonary Hypertension and Hypoxia-Inducible Factor-1-α

Craig K. Docherty, PhD; Margaret Nilsen, HND; Margaret R. MacLean, MBE, PhD, FRSE, FBPhS, FRSB

**Background**—Women are at greater risk of developing pulmonary arterial hypertension, with estrogen and its downstream metabolites playing a potential role in the pathogenesis of the disease. Hypoxia-inducible factor-1-α (HIF1α) is a pro-proliferative mediator and may be involved in the development of human pulmonary arterial hypertension. The estrogen metabolite 2-methoxyestradiol (2ME2) has antiproliferative properties and is also an inhibitor of HIF1α. Here, we examine sex differences in HIF1α signaling in the rat and human pulmonary circulation and determine if 2ME2 can inhibit HIF1α in vivo and in vitro.

**Methods and Results**—HIF1α signaling was assessed in male and female distal human pulmonary artery smooth muscle cells (hPASMCs), and the effects of 2ME2 were also studied in female hPASMCs. The in vivo effects of 2ME2 in the chronic hypoxic rat (male and female) model of pulmonary hypertension were also determined. Basal HIF1α protein expression was higher in female hPASMCs compared with male. Both factor-inhibiting HIF and prolyl hydroxylase-2 (hydroxylates HIF leading to proteosomal degradation) protein levels were significantly lower in female hPASMCs when compared with males. In vivo, 2ME2 ablated hypoxia-induced pulmonary hypertension in male and female rats while decreasing protein expression of HIF1α. 2ME2 reduced proliferation in hPASMCs and reduced basal protein expression of HIF1α. Furthermore, 2ME2 caused apoptosis and significant disruption to the microtubule network.

**Conclusions**—Higher basal HIF1α in female hPASMCs may increase susceptibility to developing pulmonary arterial hypertension. These data also demonstrate that the antiproliferative and therapeutic effects of 2ME2 in pulmonary hypertension may involve inhibition of HIF1α and/or microtubular disruption in PASMCs. *(J Am Heart Assoc. 2019;8:e011628. DOI: 10.1161/JAHA.118.011628.)*

**Key Words:** 2-methoxyestradiol • HIF1α • pulmonary arterial hypertension • pulmonary hypertension • pulmonary vascular changes • sex hormones • smooth muscle cell

Pulmonary arterial hypertension (PAH) is a progressive disease characterized by pulmonary arterial tone dysfunction and hyperproliferation of pulmonary arterial smooth muscle cells (PASMCs). Women have a greater risk of developing PAH, with registries reporting the female-to-male ratio as high as 4:1.1,2 The role of estrogen (E2) and estrogen metabolism in the development of PAH has been studied extensively. Indeed, estrogen and its downstream metabolite 16α-hydroxyestrone have been demonstrated to be involved in pro-proliferative responses in PASMCs and may be involved in the development of the human disease.3–8 Studies have also suggested a potential protective role for estrogen metabolites such as 2-hydroxyestradiol, 4-hydroxyestradiol, and 2-methoxyestradiol (2ME2). These can inhibit smooth muscle cellular proliferation and/or reverse experimental pulmonary hypertension (PH).5,9,10 2ME2 is perhaps the best studied of these metabolites and has been shown to reverse PH in the bleomycin and monocrotaline rat models.9,11,12 However, the mechanism as to how 2ME2 mediates this protective effect in the pulmonary system is unknown. 2ME2 has also been postulated to be beneficial in other hyperproliferative disease states such as cancer. Here, 2ME2 may arrest abnormal cellular growth and migration by disruption of the cytoskeletal network through depolymerization and disorganization of α-tubulin.13,14 This, in turn, has been shown to have a detrimental effect on hypoxia-inducible factor-1-α (HIF1α) stability and function.13 HIF1α is a crucial mediator of many cellular functions. Under normoxic conditions, HIF1α...
Clinical Perspective

What Is New?

- We have shown that hypoxia-inducible factor-1-α (HIF1α) protein expression is increased in female pulmonary artery smooth muscle cells (PASMCs) compared with male PASMCs and that the regulatory mechanisms that govern HIF1α expression and activity are lower in female PASMCs.

- This study has also shown that 2-methoxyestradiol is an effective inhibitor of HIF1α, both in vivo and in vitro.

- We have also demonstrated that 2-methoxyestradiol can affect PASMC microtubule structure, which may further contribute to its antiproliferative properties.

What Are the Clinical Implications?

- Increased HIF1α expression and activity is associated with many hyperproliferative disease states, including pulmonary arterial hypertension.

- Women are at greater risk of developing pulmonary arterial hypertension; therefore, increased basal expression of HIF1α may predispose female PASMCs to a state of increased proliferative capacity and contribute to pulmonary artery wall remodeling.

- Furthermore, inhibition of HIF1α and disruption of microtubule structure with 2-methoxyestradiol may be an effective treatment to reduce or prevent pulmonary artery remodeling.

Methods

Data within this paper can be found on the University of Glasgow approved data repository (http://www.gla.ac.uk/services/datamanagement/lookingafteryourdata/preservation/repositories).

An expanded methods section is available in Data S1.

Animal Studies

All experimental procedures conform to the UK Animal Procedures Act (1986) and the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health No. 85-23, revised in 1996, as well as local institutional guidelines. We chose to study the hypoxic rat model instead of the sugen/hypoxic rat, as we have previously shown that sugen decreases HIF1α expression in hPASMCs. Briefly, male and female Sprague Dawley rats were placed in hypobaric conditions (550 mbar) for 2 weeks. Rats were then removed and dosed with a subcutaneous slow-release pellet containing either 2ME2 (1.26 mg pellet/21 days; 60 μg/kg per day) (Abcam; Cambridge, UK/Innovative Research of America; Sarasota, FL) or vehicle carrier (Innovative Research of America) for a further 2 weeks in hypoxic conditions. Normoxic animals were weight matched and dosed in an identical fashion. We chose to administer 2ME2 by slow-release pellet in an attempt to overcome the low bioavailability and short plasma half-life of 2ME2.

Hemodynamic Measurements

Right ventricular systolic pressure (RVSP) measurements and associated parameters were recorded using a Miller SPR-869 catheter and analyzed using the corresponding software (LabChart Pro version 8, ADInstruments; Dunedin, New Zealand) as described previously and in Data S1.

Right Ventricular Hypertrophy

To assess right ventricular hypertrophy, the right ventricular free wall was removed and weighed. This was then expressed as a ratio to the left ventricular wall plus septum weight.

Culture and Isolation of PASMCs

Unless otherwise stated, female and male hPASMCs were isolated from pulmonary arteries of non-PAH patients undergoing a pneumonectomy procedure (0.3–1 mm diameter) from distal portions of macroscopically normal lung tissue as described previously (http://www.gla.ac.uk/services/data...
management/lookingafteryourdata/preservation/repositories) and in Table S1. All studies on human tissue were approved by an institutional review committee, and studies conformed to local and national guidelines. Specific details on isolation of rat pulmonary artery smooth muscle cells (PASMCs) can also be found in Data S1.

**Cellular Proliferation Experiments**

Cellular proliferation was assessed manually using a hemocytometer or using the cell counting kit 8 (CCK8) assay (Dojindo; Kumamoto, Japan). See Data S1 for more details.

**Caspase Activity**

Caspase-3/7 activity was measured using the Cell Event assay (ThermoFisher; Runcorn, UK) and used according to manufacturer’s instructions. See Data S1 for more details.

**Immunoblotting**

Protein expression was assessed by immunoblotting in whole lung tissue and hPASMCs. Details of antibodies used are shown in Table S2.

**Florescent Imaging**

Cellular localization of α-tubulin in hPASMCs and rat PASMCs was assessed by immunofluorescence. See Data S1 for more details.

**TaqMan Reverse Transcription Polymerase Chain Reaction**

mRNA transcripts from hPASMCs and rat whole lung tissue were assessed by quantitative reverse transcription polymerase chain reaction. Specific dual-labeled TaqMan primer-probe sets were purchased from ThermoFisher (Table S3).

**Histopathology**

Saggital sections of lung (5 μm) were stained with elastin–picrosirius red. The number of remodeled vessels (as indicated by a double elastic lamina) per section were assessed in a blinded fashion. More details can be found in Data S1.

**Statistical Analysis**

All graphs and statistical analyses were produced and performed using Prism version 5 (GraphPad Software Inc; La Jolla, CA). All data are shown as mean±SEM and a P≤0.05 was considered statistically significant. Ratio data were log-transformed to ensure that they were normally distributed before employing parametric statistical analysis. For the comparison between vehicle and drug-treated cells, a paired t-test was employed, as cells from each patient were separated into 2 and cultured, so that cells from the same patient line were tested in the presence of vehicle and 2ME2. For comparison of 2 independent groups, a 2-tailed Student’s unpaired t-test was used. For comparison of >2 groups, a 1-way ANOVA with Tukey’s post hoc test was used.

![Figure 1](https://example.com/image.png)

**Figure 1.** HIF1α signaling in male and female hPASMCs. Representative western blot of HIF1α protein expression in male and female hPASMCs (A) and densitometric analysis (B). Representative western blots of PHD2 and FIH protein expression in male and female PASMCs (C) with densitometric analysis (D). Data are shown as mean±SEM, n=3 to 6; *P<0.05 as determined by a Student’s unpaired t-test. Membranes were cut at an appropriate point and probed for separate antibodies. Membranes were then stripped and re-probed with β-actin. FIH indicates factor-inhibiting hypoxia-inducible factor; hPASMC, human pulmonary arterial smooth muscle cells; PHD2, prolyl hydroxylase-2.

DOI: 10.1161/JAHA.118.011628
Results

Sex Differences in HIF1α Signaling

Basal protein expression of HIF1α was variable but significantly higher in female hPASMCs compared with males (Figure 1A and 1B). There was increased basal PHD2 and FIH protein levels in male hPASMCs compared with female hPASMCs (Figure 1C and D). mRNA transcript analysis revealed that there were no differences in HIF1α, PHD1, PHD2, PHD3, or Von Hippel–Lindau tumor suppressor levels between male and female hPASMCs (Figure S1A through S1E). FIH mRNA levels were significantly lower in female hPASMCs (Figure S1F). Treatment with E2 (100 nmol/L; 72 hours) caused a significant decrease in FIH mRNA levels in both male and female hPASMCs compared with vehicle controls (Figure S1G and S1H).

Effect of 2ME2 on Hemodynamic Measurements in the Chronic Hypoxic Model of PH

Chronic hypoxia caused a significant increase in RVSP, right ventricular hypertrophy, and pulmonary artery remodeling in both female and male rats (Figure 2). 2ME2 reduced RVSP in female and male rats (Figure 2A and 2B), right ventricular hypertrophy (Figure 2C and 2D) and in the percentage of remodeled vessels observed (Figure 2E and 2F).

In Vivo Effects of 2ME2 on HIF1α Expression in the Chronic Hypoxic Model

Chronic hypoxia caused an increase in HIF1α protein expression in female rat whole lung tissue, which was subsequently reduced by 2ME2 (Figure 3A and 3B). No changes in HIF1α mRNA levels were observed in whole lung tissue (Figure 3C). 2ME2 also reduced regional expression of HIF1α in the smooth muscle of distal pulmonary arteries in normoxia and hypoxia (Figure 3D).

Figure 2. Effect of 2ME2 on development of pulmonary hypertension in the chronic-hypoxic rat model. Effects of 2ME2 on RVSP in female (A) and male rats (B). Effects of 2ME2 on right ventricular hypertrophy in female (C) and male rats (D) and pulmonary artery remodeling with representative photomicrographs of lung sections stained with elastin-picrosirius red in female (E) and male rats (F). Data are shown as mean±SEM. All groups n=5; *P<0.05; **P<0.01; ***P<0.001 determined by 1-way ANOVA followed by Tukey's post hoc test. Scale bar indicates 70 μm. 2ME2 indicates 2-methoxyestradiol; Hx, hypoxic; Nx, normoxic; RVSP, right ventricular systolic pressure; Veh, vehicle.
Effects of 2ME2 on Cellular Proliferation in PASMCs

We investigated the role of 2ME2 (100 nmol/L–10 μmol/L) in the proliferative response of female hPASMCs. 2ME2 (10 μmol/L, 48 hours) caused a significant decrease in cellular number in hPASMCs compared with vehicle control (Figure 4A [cell counts] and B [CCK8 assay]). A significant reduction in proliferating cell nuclear antigen protein (PCNA) levels after 2ME2 (10 μmol/L, 48 hours) was also observed in female hPASMCs (Figure 4C).

This reduction in proliferation by 2ME2 in hPASMCs was not abrogated by the estrogen receptor (ER)α antagonist MPP, the ERβ antagonist PHTPP or the G protein–coupled estrogen receptor 1 antagonist G15 (all 100 nmol/L) (Figure 4D). 2ME2 also caused a significant reduction in the proliferative responses in isolated rat PASMCs after 48 hours (Figure S2).

Effect of 2ME2 on HIF1α Protein Expression in hPASMCs

2ME2 (10 μmol/L, 48 hours) caused a significant reduction in HIF1α protein levels and downstream HK2 expression in hPASMCs (Figure 5A and 5B, respectively).

Effects of 2ME2 on Expression of Proapoptotic and Antiproliferative Mediators

A significant increase in the proapoptotic Bcl-associated X mRNA transcript was observed in hPASMCs after treatment with 2ME2 (10 μmol/L, 48 hours) (Figure 5C). 2ME2 also caused an increase in the necroptotic mediator receptor-interacting serine/threonine–protein kinase 1 (RIPK1) in hPASMCs (Figure 5D). Furthermore, 2ME2 increased activated caspase 3/7 (Figure 5E). 2ME2 had no effect on caspase 9 or p53 mRNA transcript levels in hPASMCs or on bone morphogenetic protein receptor type II expression levels (Figure S3).

Effects of Microtubule Disrupters and 2ME2 on Cellular Morphology and Cytoskeletal Network in PASMCs

2ME2 (10 μmol/L, 48 hours) caused significant changes in cellular morphology in hPASMCs with a decrease in cellular perimeter observed (Figure S4). 2ME2 also caused disruption of the cytoskeletal α-tubulin network in both hPASMCs and rat PASMCs (Figure 6A through D) and resulted in a significant reduction in α-tubulin protein levels in female hPASMCs.
2-Methoxyestradiol and HIF1α Signaling  Docherty et al

Discussion

Here, for the first time, we have demonstrated differences in HIF1α signaling between male and female hPASMCs. We have also demonstrated the ability of 2ME2 to reverse hypoxia-induced PH in men and women and identified mechanisms by which 2ME2 may be protective in experimental PH. In the chronic hypoxic rat, we confirmed that 2ME2 caused a significant reduction in pulmonary artery remodeling, associated RVSP and right ventricular hypertrophy in both male and female rats. The most profound effect of 2ME2 was on the increased RVSP in hypoxia, which was completely reversed. This is not attributable to 2ME2-induced vasodilation, as it has been shown previously that 2ME2 is not vasoreactive in this regard. These data are consistent with the effects of 2ME2 in monocrotaline- and bleomycin-induced PH models.9,11,12 2ME2 has been reported to
be an HIF1α inhibitor, so we examined the role of HIF1α in the in vivo effects of 2ME2. Following 2ME2 administration in vivo, we observed a significant reduction in HIF1α protein levels in the whole lung, suggesting that 2ME2 can reduce HIF1α expression. Indeed, 2ME2 has been shown to cause a reduction in the HIF1α/oxidative stress pathway in the chronic hypoxic rat model.24 Similarly, we demonstrated that 2ME2 can inhibit HIF1α in hPASMCs.

We demonstrated that female hPASMCs have higher basal levels of HIF1α protein than male hPASMCs, which may be a result of increased PHD2 expression within these cells. In addition, ERβ can stabilize HIF1α in prostate cancer cell lines.25 Either of these mechanisms may lead to increased HIF1α in female hPASMCs. Notably, however, female hPASMCs have significantly lower levels of the oxygen-dependent asparaginyl hydroxylase, FIH, a crucial inhibitor of the transactivational capacity of HIF1α.26 To determine whether estrogen had any influence on FIH, we treated both male and female hPASMCs with estrogen and demonstrated that FIH mRNA levels decreased significantly. We chose to study the effects of estrogen, as it is the predominant female hormone that is known to act via estrogen receptors, whereas 2ME2 has little to no affinity for any of the estrogen receptors. Decreased FIH levels in females may increase the capacity of HIF1α to activate target genes in these cells. Furthermore, estrogen is likely to play a role in this activity through an as yet unidentified pathway. We have shown previously that female hPASMCs are more proliferative than male hPASMCs when treated with promitogenic compounds such as serotonin (5-hydroxytryptamine).5 Overall, increased basal levels of HIF1α and/or reduced inhibition of HIF1α may render female hPASMCs more susceptible to “second-hit” pro-proliferative mediators such as serotonin. Importantly, most of the cells used within this study were of postmenopausal age, as it was not possible to obtain PASMCs from younger donors; therefore, age and menopausal status cannot be ruled out as a potential factor in determining HIF1α expression and activity.

As female hPASMCs have inherently higher levels of HIF1α and women are 4 times more likely to develop PAH, we chose to focus solely on female hPASMCs to determine what effect the molecular mechanisms of 2ME2 treatment may have on these cells. 2ME2 caused a significant reduction in proliferation in
hPASMCs and female rat PASMCs. Indeed, this concentration range is consistent with previous findings in other cell types, and hPASMCs that have shown a significant reduction in cellular number after 2ME2 treatment.\(^{11,27}\) This antiproliferative effect was observed in the presence of estrogen receptor antagonists and suggests that 2ME2 is not acting through classical estrogen receptors to have its antiproliferative effect in hPASMCs. This is consistent with previous reports that 2ME2 has little or no affinity for estrogen receptors but does bind to tubulin.\(^{28}\)

Despite the fact that the receptors that mediate the biological effect of 2ME2 remain ill defined, it is reported to have numerous cardiovascular protective effects including inhibition of endothelin-1, production of prostacyclin, nitric oxide production, and antioxidant effects.\(^{29}\) In addition, it has been proposed previously that 2ME2 may mediate some, but not all, of the antiproliferative effects of estrogen, effects that are independent of estrogen receptors.\(^{29}\) The antiproliferative effects of estrogen are known to be mediated by both estrogen receptor–dependent and independent mechanisms. Indeed, we have shown previously that proliferation of hPASMCs can be mediated by the ER\(\alpha\) receptor associated with mitogen-activated protein kinase and Akt signaling.\(^{30}\) 2ME2 induced a significant decrease in basal levels of HIF1\(\alpha\) protein in non-PAH hPASMCs. A reduction in HIF1\(\alpha\) levels may well lead to the less proliferative phenotype observed after treatment with 2ME2. Interestingly, 2ME2 caused a significant decrease in the downstream protein HK2 hPASMCs. HK2 is one of many well-defined HIF1\(\alpha\) target genes and a crucial component of the glycolytic pathway. Metabolic switching to a more glycolytic phenotype in both experimental PH and PAH has been stated previously\(^{18,31,32}\); therefore, assessing HK2 expression in our model was an important indicator of both the metabolic state and HIF1\(\alpha\) activity within hPASMCs after 2ME2 treatment. Our data also suggest that 2ME2 may induce proapoptotic pathways as well as antiproliferative pathways in hPASMCs. 2ME2 induced an increase in the mitophagy-related Bcl-associated X mRNA and the necroptotic related RIPK1 mRNA where RIPK1 allows the cell to undergo cell death in the absence of caspase activity.\(^{33}\) Increases in Bcl-associated X expression with 2ME2 has been detailed previously in an epithelial cancer cell line.\(^{34}\) Increased activity of caspase 3/7 provides further evidence for an apoptotic phenotype. These factors may well be

Figure 6. Assessment of \(\alpha\)-tubulin organization and expression after treatment with 2ME2. \(\alpha\)-tubulin cellular localization in female rat PASMCs (A) and after 2ME2 (10 \(\mu\)mol/L, 24 hours) (B); \(\alpha\)-tubulin cellular localization in female hPASMCs (C) and after 2ME2 (10 \(\mu\)mol/L, 24 hours) (D). Effect of 2ME2 (10 \(\mu\)mol/L, 24 hours) on protein expression levels of \(\alpha\)-tubulin protein expression in female hPASMCs (E). Data are shown as mean±SEM. *\(P<0.05\). Statistical analysis: Panel E determined by paired t-test. Scale bar indicates 50 \(\mu\)m. 2ME2 indicates 2-methoxyestradiol; hPASMCs, human pulmonary arterial smooth muscle cells; PASMCs, pulmonary arterial smooth muscle cells; Veh, vehicle.
central to the reduced number observed in female hPASMCs in the presence of 2ME2. The apoptotic phenotype in PASMCs caused by 2ME2 may not be surprising on the basis of previous observations in other cell types.27,35,36 We also observed a disruption of microtubules in both human and rat PASMCs; microtubule disruption has long been postulated to be a potential treatment in hyperproliferative cells.37 There is also evidence that microtubule disruption causes apoptotic cell death as a result of dysfunctional protein trafficking,38,39 which may play a role in the effects of 2ME2 in hPASMCs. Furthermore, microtubule disruption has been demonstrated to inhibit HIF1α in many cell types.13,23,40,41 Previous experiments have shown that 2ME2 can inhibit microtubule polymerization through 2ME2 binding to tubulin at or near the colchicine-binding site.42 This microtubule disruption may also contribute to the reduced perimeter and increased cellular size observed within the hPASMCs treated with 2ME2 as both α- and β-tubulin monomers are important for regulating cellular shape, motility, and division.43 Interestingly, we also observed a reduction in α-tubulin protein levels in hPASMCs in the presence of 2ME2. It is unknown whether this is a negative feedback response in reaction to altered α-tubulin structure and dynamics. Previous studies in renal cells have noted a similar effect in response to the microtubule disruptors vincristine and dolastatin.44 This study also showed that hPASM microtubules were stabilized with taxol and disrupted with colchicine. Interestingly, a recent study has also demonstrated that colchicine was effective in reversing experimental PH by improving right ventricular function and pulmonary hemodynamics.45 Taken together, this further suggests that microtubule disruption may be a potential therapeutic avenue in the treatment of pulmonary hypertension.

Conclusions

Estrogen is considered an important factor in female PAH patients, both before and after menopause, and men with PAH. Indeed, it has been shown recently that plasma estrogen levels are elevated in postmenopausal female PAH patients as well as men with idiopathic PAH.46,47 In addition, the levels of estrogen were associated with disease severity.

Higher levels of HIF1α in female hPASMCs may make them more susceptible to promitogenic agents and subsequent pulmonary vascular remodeling. 2ME2 has multiple mechanisms of action that are cell and tissue specific. Here, we show that the antiproliferative effects of 2ME2 are not mediated through any of the estrogen receptors. In female hPASMCs, in vitro, 2ME2 lowers HIF1α protein expression and has both antiproliferative and proapoptotic properties. Furthermore, 2ME2 also causes significant microtubule disruption which is likely to be the mechanism behind reduced HIF1α levels and the anti-proliferative effect of 2ME2 in these cells. In vivo, 2ME2 reversed hypoxia-induced PH and reduced lung HIF1α expression. These data suggest that disrupting microtubules and thereby inhibiting HIF1α may be a plausible translational target for PAH. Figure S7 summarizes our findings, suggesting a possible mechanism of action for 2ME2.

Acknowledgments

The authors thank Professor Nicholas Morrell (Cambridge, UK) for supplying the human pulmonary artery smooth muscle cells, and Lynn Loughlin for her technical assistance. The authors also thank Glasgow Caledonian University for the use of the LSM-800 confocal microscope, and Dr Patricia Martin for her assistance, as well as Dr John McClure (University of Glasgow) for his assistance with statistical analysis. Author contributions: involvement in the conception, hypotheses delineation, and design of the study: C.K.D., M.R.M; acquisition of the data or the analysis and interpretation of such information: C.K.D., M.R.M., M.N; writing of the article or substantial involvement in its revision prior to submission: C.K.D., M.R.M.

Sources of Funding

This article was funded by the British Heart Foundation grants PG/15/63/31659 and RG/16/2/32153.

Disclosures

None.

References

1. Ling Y, Johnson MK, Kiely DG, Condiffe R, Elliot CA, Gibbs JS, Howard LS, Pepke-Zaba J, Sheares KK, Corris PA, Fisher AJ, Lordan JL, Gaine S, Coghlan JG, Wort SJ, Gatzoulias MA, Peacock AJ. Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland. Am J Respir Crit Care Med. 2012;186:790–796.

2. Farber HW, Miller DP, Poms AD, Badesch DB, Frost AE, Muros-Le Roziec E, Romero AJ, Benton WW, Elliott CG, McGoon MD, Benza RL. Five-year outcomes of patients enrolled in the realive registry. Chest. 2015;148:1043–1054.

3. White K, Johansen AK, Nilsen M, Ciuclan L, Wallace E, Paton L, Campbell A, Morecroft I, Loughlin L, McClure JD, Thomas M, Mair KM, MacLean MR. Activity of the estrogen-metabolizing enzyme cytochrome p450 1b1 influences the development of pulmonary arterial hypertension. Circulation. 2012;126:1087–1098.

4. Hood KY, Montezano AC, Harvey AP, Nilsen M, MacLean MR, Touyz RM. Nicotinamide adenine dinucleotide phosphate oxidase-mediated redox signaling and vascular remodeling by 16a-hydroxyestrone in human pulmonary artery cells: implications in pulmonary arterial hypertension. Hypertension. 2016;68:796–808.

5. Mair KM, Yang XD, Long L, White K, Wallace E, Ewart MA, Docherty CK, Morrell NW, MacLean MR. Sex affects bone morphogenetic protein type II receptor signaling in pulmonary artery smooth muscle cells. Am J Respir Crit Care Med. 2015;191:693–703.

6. Austin ED, Lahm T, West J, Tofocovic SP, Johansen AK, MacLean MR, Alzoubi A, Oka M. Gender, sex hormones and pulmonary hypertension. Pulm Circ. 2013;3:294–314.

7. Ventetuolo CE, Ouyang P, Bluemke DA, Tandri H, Barr RG, Bagiella E, Cappola AR, Bristow MR, Johnson C, Kronmal RA, Kizer JR, Lima JA, Kawut SM. Sex hormones are associated with right ventricular structure and function: the MESA-right ventricle study. Am J Respir Crit Care Med. 2011;183:659–667.

8. Ventetuolo CE, Mitra N, Wan F, Manichaikul A, Barr RG, Johnson C, Bluemke DA, Lima JA, Tandri H, Ouyang P, Kawut SM. Oestadiol metabolism and androgen receptor genotypes are associated with right ventricular function. Eur Respir J. 2016;47:553–563.
2-Methoxyestradiol and HIF1α Signaling

Docherty et al

9. Tovocic SP, Sahni EM, Madzio HK, Jackson EK, Melhem MF. Estradiol metabolites attenuate monocrotaline-induced pulmonary hypertension in rats. J Cardiovasc Pharmacol. 2005;46:430–437.

10. Tovocic SP, Zhang X, Zhu H, Jackson EK, Rafikova G, Petrusova G. 2-ethoxyestradiol is antitumorigenic and attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling. Vasc Pharmacol. 2008;48:174–183.

11. Tovocic SP, Zhang X, Jackson EK, Zhu H, Petrusova G. 2-methoxyestradiol attenuates bleomycin-induced pulmonary hypertension and fibrosis in estrogen-deficient rats. Vasc Pharmacol. 2009;51:190–197.

12. Tovocic SP, Jones T, Petrusova G. Dose-dependent therapeutic effects of 2-methoxyestradiol on monocrotaline-induced pulmonary hypertension and vascular remodeling. PLoS. 2010;3:279–295.

13. Majbrees NJ, Escuin D, LaVallee TM, Pribluda VS, Swartz GM, Johnson MS, Willard MT, Zhong H, Simmons JW, Giannakakou P. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell. 2003;3:363–375.

14. Kamath K, Okouneva T, Larson G, Panda D, Wilson L, Jordan MA. 2-Methoxyestradiol suppresses microtubule dynamics and arrests mitosis without depolymerizing microtubules. Mol Cancer Ther. 2006;5:2225–2450.

15. Greer SN, Metcalf JL, Wang Y, Ohl M. The updated biology of hypoxia-inducible factor. EMBO J. 2012;31:2448–2450.

16. Prabhapar NR, Senema GL. Adaptive and maladaptive cardiorespiratory responses to continuous and intermittent hypoxia mediated by hypoxia-inducible factors 1 and 2. Physiol Rev. 2012;92:967–1003.

17. Zhang N, Fu Z, Linke S, Chicher J, Gorman JJ, Visk D, Haddad GG, Poellinger L, Peet DJ, Powell F, Johnson RS. The asparaginyl hydroxylase FIH (factor inhibiting HIF) is an essential regulator of metabolism. Cell Metab. 2010;11:364–378.

18. Marsboom G, Toth PT, Ryan JJ, Hong Z, Wu X, Fang YH, Thenappan T, Piao L, Zhang HJ, Pogoriler J, Chen Y, Morrow E, Weir EK, Rehman J, Archer SL. Dynamin-related protein 1-mediated mitochondrial mitotic fission permits hyperpolarization of vascular smooth muscle cells and offers a novel therapeutic target in pulmonary hypertension. Circ Res. 2012;110:1484–1497.

19. Riddle SR, Ahmad A, Ahmad S, Deeb SS, Malik I, Schneider BK, Allen CB, James J, Murry DJ, Treston AM, Storniolo AM, Sledge GW, Sidor C, Miller KD. Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer. Invest New Drugs. 2014;32:2041–2049.

20. Wright AF, Ewart MA, Mair K, Nilsen M, Dempsey Y, Loughlin L, Maclean MR. Oestradiol receptor alpha in pulmonary hypertension. Cardiovasc Res. 2015;105:206–216.

21. Rafikov R, Sun X, Rafikova O, Louise Meadows D, Desai AA, Khailey Z, Yuan JX, Fineman JR, Black SM. Complex I dysfunction underlies the glycolytic switch in pulmonary hypertensive smooth muscle cells. Redox Biol. 2015;2:278–286.

22. Li M, Riddle S, Zhang H, D’Alessandro A, Plockton A, Berkova NJ, Hansen KC, Moldvan R, McKeon BA, Frid M, Kumar S, Li H, Liu H, Cimovas A, Medrano JF, Thomas MG, Iloska D, Piecota-Hlavata L, Jezek P, Pullamsetti S, Fini MA, El Kasmic KC, Zhang Q, Stennmark K. Metabolic reprogramming regulates the proliferative and inflammatory phenotype of adventitial fibroblasts in pulmonary hypertension through the transcriptional co-repressor C-terminal binding protein-1. Circulation. 2016;134:1105–1121.

23. Angara S, Bhandari V. Targeting mitochondrial dysfunction in lung diseases: emphasis on mitophagy. Front Physiol. 2013;4:384.

24. Kambrampati S, Banerjee S, Dhar K, Mehta S, Haque I, Dhar G, Majumder M, Ray G, Vanvelduizen PJ, Banerjee SK. 2-methoxyestradiol inhibits Barrett’s esophageal adenocarcinoma growth and differentiation through differential regulation of β-catenin-E-cadherin-axis. Mol Cancer Ther. 2010;9:523–534.

25. Aquino-Galvez A, Gonzalez-avila G, Delgado-Tello J, Castillejos-Lopez M, Mendoza-Milla C, Zuniga J, Checa M, Maldonado-Martinez HA, Trinidad-Lopez A, Cisneros J, Torres-Espindola L, Hernandez-Jimenez C, Sommer B, Cabello-Gutierrez C, Gutierrrez-Gonzalez LH. Effects of 2-methoxyestradiol on apoptosis and HIF-1α and HIF-2α expression in lung cancer cells under normoxia and hypoxia. Oncol Rep. 2016;35:577–583.

26. Fong YC, Yang WH, Hsu SF, Hsu HC, Tseng KF, Hsu CJ, Lee CY, Scully SP. 2-methoxyestradiol induces apoptosis and cell cycle arrest in human chondrosarcoma cells. J Orthop Res. 2007;25:1106–1114.

27. Dumontet C, Jordan MA. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discovery. 2010;9:790–803.

28. Esteve MA, Carre M, Braguer D. Microtubules in apoptosis induction: are they necessary? Curr Cancer Drug Targets. 2007;7:713–729.

29. Parker AL, Kavallaris M, McCarroll JA. Microtubules and their role in cellular stress in cancer. Front Oncol. 2014;4:153.

30. Carbonaro M, Escuin D, O’Brate A, Thadani-Mulerio M, Giannakakou P. Microtubules regulate hypoxia-inducible factor-1α protein trafficking and activity: implications for taxane therapy. J Biol Chem. 2012;287:11859–11869.

31. Karna P, Rida PCG, Turaga RC, Gao J, Gupta M, Fritz A, Werner E, Yates C, Zhou J, Aneja R. A novel microtubule-modulating agent EM011 inhibits angiogenesis by repressing the HIF-1α axis and disrupting cell polarity and migration. Carcinogenesis. 2012;33:1769–1781.

32. Cushman M, He HM, Katzenellenbogen M, Giannakopoulos P. 2-Methoxyestradiol inhibits tubulin polymerization by binding to the colchicine binding site. J Med Chem. 1995;38:2041–2049.

33. Magier MA, Janke C. Post-translational modifications of tubulin. Curr Biol. 2014;24:R351–R354.

34. Huff LM, Sackett DL, Poruchynsky MS, Fojo T. Microtubule-disrupting chemotherapeutics result in enhanced proteasome-mediated degradation and disappearance of tubulin in neural cells. Can Res. 2010;70:5870–5879.

35. Prins KW, Tian L, Wu D, Thenappan T, Metzger JM, Archer SL. Colchicine depolymerizes microtubules, increases junctophilin-2, and improves right ventricular function in experimental pulmonary arterial hypertension. J Am Heart Assoc. 2017;6:e006195. DOI: 10.1161/JAHA.117.006195.

36. Ventetuolo CE, Baird GL, Barr RG, Bluemke DA, Fritz JS, Hill NS, Klinger JR, Lima JA, Ouyang P, Palesvky H, Palmisciano AJ, Krishnan I, Pinder D, Preston IR, Roberts KE, Kawut SM. Higher estradiol and lower dehydroepiandrosterone-sulfate levels are associated with pulmonary arterial hypertension in men. Am J Respir Crit Care Med. 2016;193:1168–1175.

37. Baird GL, Archer-Chico C, Barr RG, Bluemke DA, Foderaro AE, Fritz JS, Hill NS, Kawut SM, Klinger JR, Lima JAC, Mullin CJ, Ouyang P. Lower DHEA-S levels predict disease and worse outcomes in post-menopausal women with idiopathic, connective tissue disease- and congenital heart disease-associated pulmonary arterial hypertension. Eur Respir J. 2018;51:1800467.
SUPPLEMENTAL MATERIAL
Expanded Materials and Methods

Animal studies

All experimental procedures were carried out in accordance with the United Kingdom Animal Procedures Act (1986) and with the "Guide for the Care and Use of Laboratory Animals" published by the US National Institutes of Health (NIH publication No. 85-23, revised 1996) and ethical approval was also granted by the University of Glasgow Ethics Committee. All in vivo studies and subsequent analysis were carried out blinded. There were two reasons for selecting the hypoxic rat model in this study. One was that we were focusing on the hypothesis that 2ME2 may exert its therapeutic effect via HIF1α and hence hypoxia on its own was the stimulus of choice. Secondly, we were interested in in vivo sex differences and many studies have shown that hypoxia-induced PH in rats is more severe in males than females and we wished to determine the effects of 2ME2 on these in vivo sex-dependent differences. Male and female Sprague Dawley rats weighing 200g were purchased from Envigo (Germany). Rodents were housed in a 12-hour light dark cycle with access to food and water ad libitum. For hypoxic studies, rats were placed in a hypobaric chamber for two weeks at an atmospheric pressure of 550 mbar after which they were removed for dosing. Animals were anaesthetised using 3% (v/v) isoflurane and a small incision was made in the scruff of the neck. A 3 mm slow-release pellet containing either 2ME2 (1.26 mg pellet/21 days; 60ug/kg/day) (Abcam, UK/ Innovative research of America, USA) or vehicle carrier (Innovative research of America, USA) was implanted using a 10 gauge stainless steel precision trochar
(MP-182; Innovative research of America, USA). The wound was then closed using medical grade glue (3M Vetbond, USA). Animals were allowed to recover fully before being placed back into hypobaric conditions for a further two weeks. Age and weight matched animals were also dosed in normoxic conditions for the control portion of the study using an identical procedure. No obvious irritation at implant site was observed for any animal in this study. Dosage of 2ME2 was based on previous published studies.

**Haemodynamic measurements**

Animals were anaesthetically induced in 3% (v/v) isoflurane and then maintained at approximately 2% (v/v) isoflurane supplemented with a constant flow of medical oxygen (1L/min). Right ventricular systolic pressure (RVSP) measurements were taken using a Miller (UK) SPR-869 catheter and measurements recorded using the corresponding software (LabChart Pro). The catheter was inserted into the exposed right jugular vein and guided into the right ventricle of the heart to measure right ventricular pressure.

**Right ventricular hypertrophy**

In order to assess right ventricular hypertrophy the right ventricular (RV) free wall was removed and weighed. This was then expressed as a ratio to the left ventricular wall plus septum (LV+S) weight (RV/LV+S).
Culture and isolation of PASMCs

Female and male PASMCs were isolated from pulmonary arteries of patients undergoing a pneumonectomy procedure (0.3 – 1 mm diameter) from distal portions of macroscopically normal lung tissue or from lungs of patients undergoing lung transplantation, as described previously. All human cells were isolated in Professor Nicholas Morrell’s laboratory, Cambridge, UK. Experimental procedures using hPASMCs conform to the principles outlined in the declaration of Helsinki. All cells used within this study are detailed in Table S1 and were used between passages 4 and 8. Female rat PASMCs were isolated by enzymatic digestion of intra-lobar pulmonary arteries. Briefly, connective tissue/parenchyma/adventitia was removed from the pulmonary arteries. Under sterile conditions, the pulmonary arteries were washed with PBS, cut into smaller pieces and placed into enzymatic dissociation buffer pre-heated to 37°C (Ham’s F-12 culture medium (Sigma, UK) containing 1% gentamycin, 1mg/ml type 1 collagenase, 0.125mg/ml elastase, 0.375mg/ml soybean trypsin inhibitor and 2mg/ml bovine serum albumin (Sigma, UK)). The tissue mixture was agitated gently at 37°C for 1-2 hours. Digestion mix was then passed through a 100 µm strainer and centrifuged at 1200 rpm for 3 minutes. The supernatant was removed and cells were re-suspended in fresh F12 medium (1% Penicillin-Streptomycin, 10% FBS) for passage 0. At passages 1-4 cells were grown in 4.5g/l DMEM (1% Penicillin-Streptomycin, 10% FBS; Sigma, UK). Rat PASMCs were utilised for experiments between passages 2 and 4.

Cellular proliferation experiments
Cellular proliferation was assessed manually using a haemocytometer. Briefly, cells in 12-well dishes were grown to 50-60% confluency. Cells were then quiesced in 0.2% charcoal-striped serum (CSS) for 24 hours. Media was then changed to 5% CSS and 2ME2 (Abcam, UK) or vehicle (ethanol) added to the well. After 48 hours cells were trypsinized and counted. Cellular proliferation/viability was also measured using the CCK-8 kit (Dojindo, Japan). Cells were grown in 96-well plates to 50% confluency then quiesced for 24 hours in 0.2% CSS. Cells were stimulated with 2ME2 or vehicle in 5% CSS. After for 46 hours the CCK-8 substrate was added to each well and incubated at 37°C for 2 hours. A plate reader was then used to measure the O.D. at 450nm.

**Caspase activity assay**

Cells were grown in 96-well culture dishes and stimulated for 6 hours. After 6 hours the media was removed and Cell Event reagent added for 30 mins. Fluorescent signal was then detected using a SpectraMax M2 plate reader with absorption/emission maxima of ~502/530 nm.

**Immunoblotting**

Protein expression was assessed by immunoblotting in whole lung tissue and hPASMCs. Whole lung rat samples were homogenized and lysed in RIPA buffer (Sigma, UK) containing HALT protease and phosphatase inhibitors (Thermo-Fisher, UK). hPASMCs were lysed in ice-cold 1% (v/v) lauryl maltoside/PBS (Abcam, UK) containing HALT protease and phosphatase inhibitors. Protein concentrations were
determined using BCA assay (Thermo-Fisher, UK) or by nanodrop (ND-1000 spectrophotometer (Thermo-Fisher, UK). 20μg of protein was loaded for hPASMCs and whole lung lysates, for protein identification by SDS-PAGE and immunoblotting. Protein expression was quantitated in immunoblots probed the relevant antibody by overnight incubation at 4°C. Membranes were then incubated with anti-rabbit or anti-mouse secondary antibodies. Immunoblots were developed using Pierce™ ECL Western Blotting Substrate (Thermo-Fisher, UK) or EMD Millipore Immobilon™ Western Chemiluminescent HRP Substrate (ECL) (Fisher Scientific) and normalized to beta actin (Sigma, A5441). Densitometric analysis was performed using TotalLab TL100 software. A full list of antibodies and dilutions are detailed in Table S2. In some instances blots were cut and probed for two separate antibodies. This was only carried out where proteins of interest exhibited a large difference in molecular weight and where antibodies have been validated and shown to be specific for their target. Blots where appropriate may be stripped and re-probed using loading controls.

Imaging

Cellular localisation of α-tubulin in hPASMCs was assessed by immunofluorescence. Briefly, cells were grown on glass coverslips until 50-60% confluent. Cells were then washed in PBS and fixed in 4% paraformaldehyde (PFA) for 15 minutes at room temperature. Cells were then permeabilized with 0.2% Triton X-100/PBS (Sigma, UK) and blocked with 2%BSA/PBS with 0.05% Tween-20 (Sigma, UK). α-tubulin primary antibody (1:500; Sigma, UK) was added to the coverslips and incubated overnight at 4°C. Cells were then washed in PBS and incubated with secondary
antibody for 1 hour at room temperature (Alexa goat anti-mouse 594, ThermoFisher Scientific, UK). After a further PBS wash, ProLong™ Diamond antifade mountant with DAPI (ThermoFisher Scientific, UK) was applied to the coverslips and mounted on glass slides for imaging. Images were acquired using an LSM-510 or LSM-800 laser-scanning confocal microscope (Zeiss, Germany). Brightfield images were captured using an EVOS XL core microscope (ThermoFisher Scientific). All subsequent cellular measurements were performed using ImageJ (NIH) software.

**TaqMan™ RT-PCR**

RNA was extracted by finely mincing tissue with a scalpel then placing into QIAzol solution (Qiagen, UK). Tissue was then lysed using a Qiagen Tissue lyser and RNA was extracted with miRNeasy® mini kit following the manufacturers protocol (Qiagen, UK). Cells were scraped and also lysed using QIAzol solution. RNA was quantified using a nanodrop (ND-1000 spectrophotometer (Thermo-Fisher, UK) and normalised to approximately 300ng total RNA. RNA was then reverse transcribed to cDNA using the TaqMan™ reverse transcription kit (Applied Biosystems). Semi-quantitative real-time PCR was performed using an Applied Biosystems Viia 7 real-time PCR system. Specific dual labelled TaqMan™ primer-probe sets were purchased from Thermo-Fisher, UK (Table S3). Results are expressed as a ratio to a reference gene using the $2^{-\Delta\Delta Ct}$ comparison method or as fold change when comparing drug treatments.

**Histopathology**
Pulmonary vascular remodelling was assessed using 5μm sections cut and stained using Millers elastin/Picro Sirius Red for identification of vascular remodelling, characterized by a distinctive double elastic lamina. The total number of remodelled vessels was expressed over the total number of vessels present in a lung section as assessed in a blinded fashion.
Table S1. Patient details of non-PAH male and female hPASMCs used within this study.

| Cell type | Patient Sex | Patient details       | Patient age |
|-----------|-------------|-----------------------|-------------|
| Non-PAH   | Female      | Mild emphysema        | 64          |
| Non-PAH   | Female      | Adenocarcinoma        | 71          |
| Non-PAH   | Female      | Emphysema             | 57          |
| Non-PAH   | Female      | Lung carcinoma        | 70          |
| Non-PAH   | Female      | Squamous carcinoma    | 57          |
| Non-PAH   | Female      | n/a                   | 56          |
| Non-PAH   | Female      | Squamous carcinoma    | 59          |
| Non-PAH   | Female      | Mild emphysema        | 58          |
| Non-PAH   | Female      | n/a                   | 64          |
| Non-PAH   | Male        | Emphysema             | 62          |
| Non-PAH   | Male        | n/a                   | 72          |
| Non-PAH   | Male        | Squamous carcinoma    | 60          |
| Non-PAH   | Male        | Adenocarcinoma        | 78          |
| Non-PAH   | Male        | n/a                   | n/a         |
| Non-PAH   | Male        | Adenocarcinoma        | 52          |
| Non-PAH   | Male        | Lung cancer (unknown) | 75          |
Table S2. Antibodies and dilutions used for Western blotting (WB) or immunofluorescence (IF).

| Antibody   | Type   | Supplier (catalogue #)                  | Dilution          |
|------------|--------|----------------------------------------|-------------------|
| HIF1α      | Rabbit | Novus Biologicals (NB100-105)          | WB 1:500          |
| HIF1α      | Mouse  | BD Bioscience (610958)                 | WB 1:500          |
| PCNA       | Rabbit | Abcam (2426)                           | WB 1:200          |
| Hexokinase 2 | Rabbit | Cell Signaling (2867)                 | WB 1:1000         |
| PHD2       | Rabbit | Cell Signaling (4835)                 | WB 1:1000         |
| FIH        | Rabbit | Novus Biologicals (NB100-428)         | WB 1:500          |
| BMPR2      | Mouse  | BD Bioscience (612292)                 | WB 1:500          |
| α-tubulin  | Mouse  | Abcam (7294)                           | WB 1:5000         |
| β-actin    | Mouse  | Sigma (A5441)                          | WB 1:5000         |
| Gene    | Target | Assay ID   |
|---------|--------|------------|
| HIF1α   | Rat    | Rn01472831 |
| HIF1α   | Human  | Hs00153153 |
| PHD1    | Human  | Hs00914594 |
| PHD2    | Human  | Hs00990001 |
| PHD3    | Human  | Hs00420085 |
| VHL     | Human  | Hs00184551 |
| FIH     | Human  | Hs00215495 |
| Bax     | Human  | Hs00180269 |
| RIPK1   | Human  | Hs01041869 |
| BMPR2   | Human  | Hs00176148 |
| Caspase9| Human  | Hs00962278 |
| TP53    | Human  | Hs01034249 |
Figure S1. HIF1α signaling in female hPASMCs.

A) HIF1α

B) PHD1

C) PHD2

D) PHD3

E) VHL

F) FIH

G) Male FIH

H) Female FIH
mRNA transcript expression levels of HIF1α (A) Prolyl hydroxylase 1 (PHD1; B),
Prolyl hydroxylase 2 (PHD2; C), Prolyl hydroxylase 3 (PHD3, D), Von-Hippel Lindau
tumour suppressor (VHL; E) and Factor inhibiting HIF (FIH, F). Effect of 72 hours
treatment with 100nM E2 on FIH mRNA expression in male (G) and female (H)
hPASMCs. Data is shown as mean ± SEM. ★ p<0.05; ★ ★ p<0.01 determined by
unpaired or paired t-test. hPASMC, human pulmonary arterial smooth muscle cells;
Veh, vehicle.
Figure S2. Effect of 2ME2 on the cellular proliferation of rat PASMCs.

Effect of 2ME2 (100nm-10µM) on FBS-induced proliferation in isolated rat female PASMCs assessed by manual cell counts (A) and CCK8 assay (B) after 48 hours (n=5 and 4, respectively). Data is shown as mean ±SEM. ★ p<0.05; ★★ p<0.01; ★★★ p< 0.001 determined by one way ANOVA followed by Tukey’s post-hoc test.

Veh, vehicle.
Figure S3. Effects of 2ME2 on pro-apoptotic genes in female hPASMCs.

Effect of 2ME2 (10µM, 48 hrs) on mRNA transcript expression levels of caspase 9 (A) and p53 (B) in female hPASMCs. BMPR2 mRNA (C) and protein expression (D) in female PASMCs. Data is shown as mean ± SEM. Statistical analysis determined by paired t-test. hPASMC, human pulmonary arterial smooth muscle cells.
Figure S4. Morphological changes in female hPASMCs associated with 48 hours 2ME2 treatment.

Bright field images after 1%CSS (A), 5% CSS (B), 100nM 2ME2 (C), 1µM 2ME2 (D), 10µM 2ME2 (E) and vehicle (F). Cellular perimeter measurements in female hPASMCs in presence of 10µM 2ME2 (G) (n=3). Scale bar indicates 70µm. Veh, vehicle; hPASMC, human pulmonary arterial smooth muscle cells.
Figure S5. Comparison of morphological changes in female hPASMCs after stimulation with various microtubule mediators.

Bright field images after 24 hours treatment with Taxol (10 μM), Colchicine (10 μM) and 2ME2 (10 μM) (n=3). hPASMC, human pulmonary arterial smooth muscle cells.

Scale bar indicates 70μm.
Figure S6. Effects of microtubule mediators on α-tubulin organization in female hPASMCs.

High resolution confocal microscopy images of α-tubulin after treatment with Taxol (10 μM), Colchicine (10 μM) and 2ME2 (10 μM) (n=3) with increased digital magnification (inset). hPASMC, human pulmonary arterial smooth muscle cells. Arrows indicate condensing/disruption to the microtubule network. Scale bar indicates 10μm and 5μm (inset).
2ME2 causes α-tubulin dysregulation which, in turn, can cause reduced HIF1α and HK2 protein expression. Disruption of α-tubulin may also lead to increases in apoptotic genes Bax and RIPK1 and activation of caspase3/7. 2ME2, 2-methoxyestradiol; HK2, hexokinase 2; Bax, Bcl-associated X; RIPK1, related receptor Interacting Serine/Threonine Kinase 1. Green arrow = upregulation. Red arrow = down regulation. Blue arrow = causes/leads to.
Supplemental References:

1. Tofovic SP, Jones T, Petrusevska G. Dose-dependent therapeutic effects of 2-Methoxyestradiol on Monocrotaline-Induced pulmonary hypertension and vascular remodelling. *Prilozi*. 2010;31:279-295.

2. Dean A, Gregorc T, Docherty CK, Harvey KY, Nilsen M, Morrell NW, MacLean MR. Role of the Aryl Hydrocarbon Receptor in Sugen 5416-induced Experimental Pulmonary Hypertension. *American journal of respiratory cell and molecular biology*. 2018;58:320-330.